Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience

Publisher： Karger

E-ISSN： 1421-9662|138|1|55-60

ISSN： 0001-5792

Source： Acta Haematologica, Vol.138, Iss.1, 2017-07, pp. : 55-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients

By  

Oncology Research and Treatment, Vol. 40, Iss. 10, 2017-09 ,pp. : 616-620

Karger

Access to resources Recommend Favorite